MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-05-2024
Nektar Therapeutics DPO Ratio 2011-2026 | NKTR
Annual DPO Ratio Nektar Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123 | 192 | 234 | 388 | 328 | 87.5 | 57.1 | 34 | 25.3 | 34.6 | 86.4 | 34.3 | 50.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 388 | 25.3 | 129 |
Quarterly DPO Ratio Nektar Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 48.9 | - | 192 | 247 | 372 | 251 | 353 | 467 | 363 | 350 | 495 | 293 | 356 | 350 | 210 | 71.6 | 112 | 96.7 | 73 | 44.7 | 76.9 | 48.5 | 56.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 495 | 44.7 | 224 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alector
ALEC
|
13.8 | $ 2.19 | -9.77 % | $ 226 M |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
98.4 | $ 1.02 | 1.49 % | $ 74.9 M | USA |
 |
Cerus Corporation
CERS
|
242 | $ 2.6 | 1.37 % | $ 480 M | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cellectis S.A.
CLLS
|
975 | $ 3.87 | -0.39 % | $ 116 M |  France |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M |  Canada |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | USA |
 |
Collegium Pharmaceutical
COLL
|
34.6 | $ 41.75 | 0.19 % | $ 1.32 B | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
785 | $ 36.14 | 1.23 % | $ 3.75 B | USA |
 |
Amarin Corporation plc
AMRN
|
190 | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
Catalyst Pharmaceuticals
CPRX
|
58.1 | $ 23.77 | 2.99 % | $ 2.91 B | USA |
 |
Cardiff Oncology
CRDF
|
406 | $ 1.94 | 0.01 % | $ 130 M | USA |
 |
Curis
CRIS
|
3.24 K | $ 1.1 | -3.51 % | $ 6.94 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | Canada |
 |
CorMedix
CRMD
|
216 K | $ 7.16 | 0.42 % | $ 364 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Champions Oncology
CSBR
|
64.6 | $ 6.14 | 3.89 % | $ 83.9 M | USA |